Investments
311Funds
6Partners & Customers
1Service Providers
1About RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. The firm provides seed funding to startups and leads private, IPO, and follow-on financings for its portfolio companies, thereby driving value creation from idea inception through commercialization.
Want to inform investors similar to RA Capital Management about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing RA Capital Management
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find RA Capital Management in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing RA Capital Management
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned RA Capital Management in 1 CB Insights research brief, most recently on Aug 5, 2021.
Aug 5, 2021
Here Are The Most Active Healthcare InvestorsLatest RA Capital Management News
May 31, 2023
Carrot Therapeutics , a Berkeley, CA-based clinical-stage biotechnology company, raised $150M in Series E funding. The round was led by Deep Track Capital with participation from 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, RA Capital Management, Millennium Management, TCGX, The Column Group, Venrock Healthcare Capital Partners and Willett Advisors. The company intends to use the funds to strengthen its broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis. Led by Heather Turner, Chief Executive Officer, Carmot Therapeutics is a clinical-stage biotechnology company that is focused on the discovery and development of disease-modifying therapies for people living with metabolic diseases including obesity and diabetes. The company uses Chemotype Evolution, a drug discovery platform, to identify novel incretin receptor signaling targets and develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. It has three clinical candidates: CT-388 (once-weekly, dual GLP-1/GIP receptor modulator), CT-868 (once-daily, dual GLP-1/GIP receptor modulator) and CT-996 (oral, small molecule GLP-1 receptor agonist). FinSMEs 31/05/2023
RA Capital Management Investments
311 Investments
RA Capital Management has made 311 investments. Their latest investment was in Carmot Therapeutics as part of their Series E on May 5, 2023.
RA Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/25/2023 | Series E | Carmot Therapeutics | $150M | No | 8 | |
5/16/2023 | Series C | Boundless Bio | $100M | No | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | 7 |
5/3/2023 | Series A | Convergent Therapeutics | $90M | Yes | 6 | |
4/17/2023 | Series D | |||||
4/13/2023 | Series C |
Date | 5/25/2023 | 5/16/2023 | 5/3/2023 | 4/17/2023 | 4/13/2023 |
|---|---|---|---|---|---|
Round | Series E | Series C | Series A | Series D | Series C |
Company | Carmot Therapeutics | Boundless Bio | Convergent Therapeutics | ||
Amount | $150M | $100M | $90M | ||
New? | No | No | Yes | ||
Co-Investors | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | ||||
Sources | 8 | 7 | 6 |
RA Capital Management Fund History
6 Fund Histories
RA Capital Management has 6 funds, including RA Capital Nexus Fund III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
10/6/2021 | RA Capital Nexus Fund III | $880M | 1 | ||
10/21/2020 | RA Capital Nexus Fund II | ||||
7/15/2019 | RA Capital Nexus Fund | ||||
7/12/2019 | RA Capital Nexus International Fund | ||||
RA Capital Healthcare Fund LP |
Closing Date | 10/6/2021 | 10/21/2020 | 7/15/2019 | 7/12/2019 | |
|---|---|---|---|---|---|
Fund | RA Capital Nexus Fund III | RA Capital Nexus Fund II | RA Capital Nexus Fund | RA Capital Nexus International Fund | RA Capital Healthcare Fund LP |
Fund Type | |||||
Status | |||||
Amount | $880M | ||||
Sources | 1 |
RA Capital Management Partners & Customers
1 Partners and customers
RA Capital Management has 1 strategic partners and customers. RA Capital Management recently partnered with Xenomorph on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/5/2022 | Vendor | United Kingdom | Having completed an extensive selection process and subsequent proof of concept , RA Capital Management selected Xenomorph to deliver a comprehensive enterprise data management solution for their bio-tech and financial data needs . | 1 |
Date | 7/5/2022 |
|---|---|
Type | Vendor |
Business Partner | |
Country | United Kingdom |
News Snippet | Having completed an extensive selection process and subsequent proof of concept , RA Capital Management selected Xenomorph to deliver a comprehensive enterprise data management solution for their bio-tech and financial data needs . |
Sources | 1 |
RA Capital Management Service Providers
1 Service Provider
RA Capital Management has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type |
Partnership data by VentureSource
RA Capital Management Team
10 Team Members
RA Capital Management has 10 team members, including current Founder, Managing Partner, Peter Kolchinsky.
Name | Work History | Title | Status |
|---|---|---|---|
Peter Kolchinsky | Founder, Managing Partner | Current | |
Name | Peter Kolchinsky | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder, Managing Partner | ||||
Status | Current |
Compare RA Capital Management to Competitors
Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.
The company are a enterprise recognized in the enteral products industry as a manufacturer of high quality, yet cost-effective devices. The company supply products to domestic and international customers. The company also are a contract manufacturer focused on the development and production of equipment for the medical and life sciences industries. The company's organization is composed of individuals with years of industry experience. OST Medical has a strong commitment to the company's customers and the company are confident in the company's ability to meet customer expectations in quality, price and delivery.
ProterixBio develops products to transform the management of chronic diseases.
Otothera Corporation is a medical device company developing products to diagnose and treat the more than seven million severe tinnitus (constant ringing in the ears) sufferers in the US. The company was originally named AudioFusion. The company was a 2006 PTEN Growth Accelerator (GAP) winner.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.